Additionally, in the context of long-term treatment, ASK120067 exhibited enhanced antitumor efficacy against BCAT1-knockdown 67R tumors compared to control 67R tumors, as evidenced by tumor growth inhibition rates (TGI) of 57.46% versus 27.87% at a dose of 1 mg/kg and 69.70% versus 39.46% at a dose 2.5 mg/kg on day 63 (Fig. 3k and Supplementary Fig. 4g, h). The gene discussed is BCAT1; the disease is neoplasm.